Welcome to our dedicated page for CEL SCI SEC filings (Ticker: CVM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on CEL SCI's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into CEL SCI's regulatory disclosures and financial reporting.
CEL SCI CORP (CVM) reported that Chief Executive Officer and director Geert R. Kersten purchased 100,000 shares of restricted common stock directly from the company on August 25, 2026. The shares were bought at $1.38 per share, equal to the August 24, 2026 closing price, according to a footnote.
Following this purchase, Kersten’s reported direct holdings increased to 316,142 shares of common stock. He also reports 311,547 shares of common stock held indirectly as Trustee, shown as a separate holding entry.
CEL SCI CORP director Robert Eugene Watson reported a grant of 110,000 stock options on 2026-08-14. The options have an exercise price of $1.49 per share, an associated grant value of $0.01 per option, and expire on 2036-08-13. They vest in three equal annual installments starting one year after the grant date and are exercisable for 110,000 shares of common stock. Following this award, Watson holds 137,271 options directly.
CEL-SCI Corp (CVM) director Bruno Jean-Marie Baillavoine reported a grant of 110,000 stock options on 2026-08-14. The options have an exercise price of $1.49 per share, a nominal grant-date value of $0.01 per option, and expire on 2036-08-13. They vest in three equal annual installments commencing one year after the grant date. Following this grant, Baillavoine holds 138,021 options in total, all reported as directly owned.
CEL-SCI Corp reported that Senior Vice President John Cipriano received a grant of 80,000 stock options on 2026-08-14. The options have an exercise price of $1.49 per share, a stated value of $0.01 per option, and expire on 2036-08-13. Following this grant, Cipriano holds 118,010 options directly. According to the grant terms, the options vest in three equal annual installments starting one year after the grant date.
CEL-SCI Corp (CVM) reported that Chief Scientific Officer Talor Eyal received a grant of 250,000 options to acquire Common Stock. The options have an exercise price of $1.49 per share, expire on August 13, 2036, and vest in three equal annual installments starting one year after the grant date. Following this award, Eyal directly holds 331,625 options in total.
CEL SCI CORP Chief Financial Officer Patricia B. Prichep received a grant of stock options covering 225,000 shares of common stock. The options have an exercise price of $1.49 per share, a reported transaction price of $0.01 per option, and expire on August 13, 2036. They vest in three equal annual installments beginning one year after the grant date. Following this award, she holds 299,693 options in total.
CEL SCI CORP director and Chief Executive Officer Geert R. Kersten received a grant of 300,000 stock options on 2026-08-14. The options have an exercise price of $1.49 per share, a grant-date fair value of $0.01 per option, and expire on 2036-08-13. They vest in three equal annual installments starting one year after the grant date. Following this grant, Kersten directly holds 452,380 options in total.
CEL-SCI Corporation held its annual shareholder meeting on August 14, 2026, where shareholders elected three directors for the upcoming year. Geert Kersten received 4,371,909 votes for and 478,675 withheld; Bruno Baillavoine received 2,188,254 for and 2,662,330 withheld; Robert Watson received 2,062,150 for and 2,788,434 withheld, with 4,365,596 broker non-votes for each director.
Shareholders approved CEL-SCI’s 2026 Non-Qualified Stock Option Plan, 2026 Stock Bonus Plan, a non-binding advisory vote on executive compensation, and ratified BDO USA, LLP as independent registered public accounting firm for the fiscal year ending September 30, 2026. For these proposals, votes for ranged from 3,654,395 to 8,638,163. On the advisory vote regarding the frequency of say-on-pay, shareholders cast 1,692,789 votes for one year, 158,296 for two years, and 2,668,661 for three years, with 330,838 abstentions.
CEL-SCI Corporation reported continued operating losses and tight liquidity for the nine months ended June 30, 2026 while advancing its cancer immunotherapy program Multikine toward a planned confirmatory Phase 3 registration study. The company generated no revenue and recorded a net loss of $16.6 million, modestly improved from $19.3 million a year earlier, driven by lower research and development and general and administrative expenses.
Total assets declined to $21.4 million from $28.2 million, with cash and cash equivalents falling to $6.5 million from $11.0 million. Net cash used in operating activities was $12.1 million, partly offset by $9.7 million of equity financing proceeds and officer purchases, resulting in a $4.4 million cash decrease. Stockholders’ equity fell to $11.0 million from $16.0 million, and the accumulated deficit widened to $556.0 million.
Management explicitly states there is substantial doubt about the company’s ability to continue as a going concern, citing recurring losses and future liquidity needs. To fund a 212‑patient Multikine confirmatory registration study, the cost is estimated at $30–$35 million, and additional financing through partnerships, debt, or equity will be required.